TB advocates
By
TB advocates
Published: April 4, 2020, 2:12 p.m.·
Tags:
Diagnostics,
Access,
Advocacy
Advocates request Cepheid immediately reduce the price of Xpert tests to $5, inclusive of service and maintenance; Cepheid claims costs for each Xpert cartridge "substantially exceed" the requested price target of $5, but does not provide evidence to support this claim.
Read More →
By
TB Alliance,
TB advocates
Published: Aug. 30, 2019, 9:41 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Access,
Advocacy
Pretomanid receives FDA approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB.
Read More →
By
TB advocates
Published: July 30, 2019, 10:34 p.m.·
Tags:
Drug-resistant TB,
Access,
Advocacy
Advocates request responsible investment in pretomanid promoting transparency and equitable access.
Read More →
By
TB advocates
Published: June 16, 2019, 10:24 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Access,
Advocacy
Activists storm the corporate stall of Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) at the 9th South African AIDS Conference.
Read More →
By
TB advocates
Published: June 12, 2019, 5:34 p.m.·
Tags:
Access,
Advocacy
Advocates request full access to the terms of the agreement granting Mylan the rights to commercialize pretomanid.
Read More →
By
TB Alliance,
TB advocates
Published: June 9, 2019, 9:43 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Advocacy
Investigational drug pretomanid is under regulatory review by FDA for treatment of XDR-TB and treatment-intolerant or non-responsive MDR-TB as part of a new investigational regimen.
Read More →
By
TB advocates,
civil society organizations
Published: May 4, 2019, 7:30 p.m.·
Tags:
Drug-resistant TB,
TB programs,
Treatment,
Access,
Advocacy,
Pharma industry
Advocates call on Indian Minister of Health to discontinue and phase out the drug donations of bedaquiline offered by Johnson & Johnson.
Read More →
By
TB advocates
Published: Jan. 7, 2019, 3:48 p.m.·
Tags:
TB programs,
Drug-resistant TB,
Treatment,
Diagnostics,
Access,
Advocacy,
TB CAB
Advocates call for minimizing the use of injectable agents and scaling up universal drug susceptibility testing.
Read More →
By
TB advocates
Published: Jan. 7, 2019, 3:31 p.m.·
Tags:
TB programs,
Diagnostics,
Access,
Advocacy,
TB CAB
Advocates call for removal of regulatory barriers, which contributed to the ongoing national stock out of GeneXpert MTB/RIF cartridges.
Read More →
By
civil society,
TB advocates
Published: July 13, 2018, 10:02 a.m.·
Tags:
Drug-resistant TB,
Treatment,
Access,
Advocacy
Advocates request that bedaquiline become part of the standard treatment regimen for drug-resistant TB in India.
Read More →
Page 1 of 5 · Total posts: 10
1
2
Last→